semaglutide vs ozempic side effects GLP-1 vs Wegovy vs Mounjaro Ozempic side-effects & management: Ozempic

Learn more about the symptoms, causes and treatment options today!

Drugs known as GLP-1 receptor agonists were initially developed to treat Type 2 diabetes but have become a cultural phenomenon.

The rate constant was 0.0302 per week (95% CI 0.0204-0.0399), corresponding to a half-life of 23.0 weeks

Promising therapeutics include semaglutide (Ozempic and Wegovy), an agonist for glucagon-like peptide-1 (GLP-1) receptor, and tirzepatide (Mounjaro), a dual agonist for GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors

95% CI] -0.12% [0.18, 0.06]

Lo dimostra uno studio svolto su 3533 persone, met delle quali trattate con 1 mg alla settimana di semaglutide (nome commerciale Ozempic)